Objective A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life-cycle allow testing of a multi-stage multi-component vaccine for the first time, with strong chances of success. These advances are i) the availability of a new vectored prime-boost vaccination regime based on the ReiThera Srl's chimpanzee adenovirus technology that has been found to induce exceptionally potent CD8+ T cell responses and high titre antibodies against multiple malaria antigens; ii) the development of an improved version of the leading partially protective RTS,S sporozoite vaccine candidate, termed R21, that lacks the excess of HBsAg in RTS,S; iii) the identification, using a vector technology screen, of the blood-stage antigen RH5 as the first antigen to induce potent strain-transcending neutralisation of blood-stage parasites in in vitro growth inhibition assays; and iv) the demonstration that vector-induced antibodies against two mosquito-stage antigens can induce 100% transmission blocking against field isolates of P. falciparum in Africa.We will undertake four phase I / II clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components individually, and then together, using state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product. Fields of science medical and health scienceshealth sciencesinfectious diseasesmalariamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2012.2.3.2-3 - Prevention and treatment for HIV/AIDS, malaria and tuberculosis Call for proposal FP7-HEALTH-2012-INNOVATION-1 See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD EU contribution € 4 724 875,50 Address WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford United Kingdom See on map Region South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all REITHERA SRL Italy EU contribution € 650 000,00 Address VIA DI CASTEL ROMANO 100 00128 Roma See on map Region Centro (IT) Lazio Roma Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data EUROPEAN VACCINE INITIATIVE EWIV Germany EU contribution € 300 000,00 Address VOSSSTRASSE 2 GEB 4040 69115 Heidelberg See on map Region Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 France EU contribution € 300 000,00 Address Place Jussieu 4 75252 PARIS See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data GLAXOSMITHKLINE VACCINES SRL Participation ended Italy EU contribution € 124,50 Address VIA FIORENTINA 1 53100 SIENA See on map Region Centro (IT) Toscana Siena Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data GLAXOSMITHKLINE BIOLOGICALS SA Belgium EU contribution € 25 000,00 Address RUE DE L INSTITUT 89 1330 Rixensart See on map Region Région wallonne Prov. Brabant Wallon Arr. Nivelles Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data